Our study included the recently updated ADJUVANT and ADAURA studies, further confirming that adjuvant therapy with EGFR‐TKIs significantly improved DFS with a reduced recurrence risk of 62% in patients with stage IB–IIIA NSCLC who had undergone radical resection with positive EGFR mutations when compared with adjuvant chemotherapy or placebo treatment. Here, EGFR is linked to non-small cell lung carcinoma.